Abstract
We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-Nω nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.
| Original language | English |
|---|---|
| Pages (from-to) | 262-267 |
| Number of pages | 6 |
| Journal | Japanese Journal of Thoracic Diseases |
| Volume | 33 |
| Issue number | 3 |
| Publication status | Published - 1995 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
Fingerprint
Dive into the research topics of 'Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver